Daratumumab - Latest Advances

Frequency-adjusted daratumumab-based regimen versus bortezomib/dexamethasone in newly diagnosed AL amyloidosis: a matched-cohort study.

Journal: Annals of medicine

Published: January 21, 2026

Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 06, 2026

Prognostic significance of cardiac biomarkers in patients with AL amyloidosis treated with a daratumumab-based regimen.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Published: January 06, 2026

Effect of different induction chemotherapy regimens on autologous hematopoietic stem cell mobilization in patients with multiple myeloma in the new drug era

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: January 05, 2026

Evaluation of the performance of new daratumumab-specific immunofixation electrophoresis reflex agent and the timing of M-protein measurement.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: December 24, 2025

The Story of Localized Amyloidosis: Something Old and Something New - A Case Series.

Journal: Journal of investigative medicine high impact case reports

Published: December 18, 2025

Daratumumab bortezomib and dexamethasone in transplant ineligible newly diagnosed elderly myeloma patients (AMN006)-a trial by Asian Myeloma Network (NCT03695744).

Journal: Leukemia & lymphoma

Published: December 16, 2025

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; encorafenib for colorectal cancer, daratumumab for multiple myeloma, repotrectinib for NTRK-fusion positive solid tumors, and venetoclax for leukemia.

Journal: International journal of clinical oncology

Published: December 15, 2025

Effective front-line treatment of osteosclerotic myeloma with POEMS syndrome with daratumumab, lenalidomide and dexamethasone: a case report and literature review.

Journal: Acta clinica Belgica

Published: December 12, 2025

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.

Journal: The New England journal of medicine

Published: December 09, 2025

A new validated staging system for AL amyloidosis with Stage IIIC defining ultra-poor risk: AL International Staging System (AL-ISS).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 07, 2025

New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 07, 2025